WIN-x Synthetic Cannabinoids Cannabinoid Research

WIN-x Synthetic Cannabinoids Properties and Effects

WIN 55,212-2 may: 

• Induce apoptosis is glioblastoma (A. Ellert-Miklaszewska et al., 2021)


• Induce modulate dopamine with potential relevance to the effects of heroin (D. Gomez et al., 2021)


• Induce neuroprotection and anti-inflammatory effects (D. Spyridakos et al., 2021)


• Prevent the development of and/or attenuated established HIV-NP (E. Aly et al., 2021)


• Mitigate SARS-CoV-2 pathology (L. Aragão et al., 2021)


• Mitigate prostate cancer via CB2 (L. Pietrovito et al., 2020)


• Mitigate cerebral hypoperfusion and associated cognitive decline (Da-Peng Wang et al., 2020)


• Initiate therapeutic effects in human with MS (J. Tomas-Roig et al., 2020)


• Co-adm. of Tramadol and WIN-55212 chronic neuropathies (M. Alsalem2020)


• Neuroprotective (Z. Elmazoglu et al., 2020)


• Increase the risk of headache medication overuse (C. Kopruszinski et al., 2020)


• Worsen effects of METH (C. Dong et al., 2019)


• Reduce cancer metastatic leukemia cell invasiveness (F. Gholizadeh et al., 2019)


• Reduce pain in breast cancer (A. de Almeida et al., 2019)


• Mitigate signs and symptoms of myasthenia gravis (M. Morsch et al., 2018)


• Inhibits renal cell carcinoma (M. Khan et al., 2018)


• Diminish signs and symptoms of severe stress (O. Burstein et al., 2018)


• Antipruritic (K. Bilir et al., 2018)


• Anti-Myeloma Activity (M. Barbado et al., 2017)


• Mitigate hyperexcitability-based diseases (F.o Carletti et al., 2016)


• Reduce consequences of status epilepticus (E. Suleymanova et al., 2016)


• Decreases inflammation with potential relevance to rheumatoid arthritis (T. Lowin et al., 2016)


• Improves the HD-like symptoms in mice (S. Pietropaolo et al., 2015)


• Inhibit metastasis of liver cancer cells (D. Xu et al., 2015)


• Prevented the effects of shock (N. Korem et al., 2014)


• Inhibit 5-fluorouracil-resistant gastric cancer cells (Xiang-Shu Xian et al., 2013)


• Treat stress-induced noradrenergic dysfunction (B. Reyes et al., 2012)


• Reduced sperm ATP levels via CB1 (D. Morgan et al., 2012)


• Reduces (Aβ)-induced neurodegeneration via PPAR-gamma (G. Fakhfouri et al., 2012)


• Inhibited tumor growth and lung metastasis (~50%) in test animals (A. Preet et al., 2012)


• Induce significant analgesia in rodents with spinal cord injury (A. Hama et al., 2011; A. Hama et al., 2009)


• Cause cell cycle arrest in gastric cancer (J. Park et al., 2011)


• Represent a potential treatment for melanoma (M. Scuderi et al., 2011)


• Induce apoptosis in lymphoma cells (A. Wasik et al., 2011)


• Reduce symptoms of Parkinson's (Y. Chung et al., 2011; D. Price et al., 2009)


• Mitigate skin and lung fibrosis (A. Servettaz et al., 2010)


• Induce direct anti-atherosclerotic effects (Y. Zhao et al., 2010)


• Abrogate the growth of endometriotic tissue (M. Leconte et al., 2010)


• Inhibit gastric cancer cells (X. Xian et al., 2010)


• May not be effective in the treatment of salicylate-induced tinnitus (Y. Zheng et al., 2010)


• Reduce oral inflammatory pain as effective as morphine (E. Burgos et al., 2010)


• Modulate inflammatory disease (O'Sullivan et al., 2010)


• Make a shift from pathological to normal aging (Y. Marchalant et al., 2009)


• Induce anti-fibrogenic effect (E. Garcia-Gonzalez et al., 2009)


• Reduces viability of human Kaposi's sarcoma cells (T. Luca et al., 2009)


• Induce apoptosis of liver cancer cells (M. Giuliano et al., 2009)


• Downregulate adhesion molecules in multiple sclerosis (L. Mestre et al., 2009)


• Induce gastro-protective effect via CB1 (N. Shujaa et al., 2009)


• Inhibited metastasis of breast cancer in test animals (Z. Qamri et al., 2009)


• Mitigate diabetic neuropathy (M. Bujalska 2008)


• Induce apoptosis in thyroid cancer cells via CB2 (Y. Shi et al., 2008)


• Inhibit cervical carcinoma cells (M. Rudolph et al., 2008)


• Produce anti-inflammatory effect in rheumatoid model (E. Selvi et al., 2008)


• Decreased inflammation and increase viral load in the CNS (R. Herrera et al., 2008)


• Reduce pain in model of TMJ (M. Lee et al., 2008; D. Ahn et al., 2007)


• Reduce zoster-associated pain (F. Hasnie et al., 2008)


• Reduce pain via peripheral CB1 in nociceptors (N. Agarwal et al., 2007)


• Reduce LPS-induced fever (K. Benamar et al., 2007)


• Induce antidepressant effects (F. Bambico et al., 2007)


• Stop radiation-induced emesis (N. Darmani et al., 2007)


• Delay disease progression in model of ALS (L. Bilsland., 2006)


• Reduced viability of ovarian cancer cells (R. McKallip et al., 2006)


• Neuroprotective in Alzheimer's (B. Ramırez et al., 2005)


• Produce apoptosis in prostate cancer cell line (S. Sarfaraz et al., 2005)


• R(+)WIN55,212 reduced cardiac inflammation but led to increased parasitaemia (J. Croxford et al., 2005)


• Reduce mantle cell lymphoma cell growth (J. Flygare et al., 2005)


• Induce antinociception in diabetic mice (A. Doğrul et al., 2004)


• Treat diabetic neuropathy (A. Ulugol et al., 2004)


• Inhibit malignant skin tumors (M. Casanova et al., 2003)


• Reduce neuropathic pain (G. Lim et al., 2003)


• Inhibited gastroesophageal acid reflux in TLESR (A. Lehmann et al. 2002)


• Ameliorated tremors and spasticity in multiple sclerosis (D. Baker et al., 2000)


• Reduced intraocular pressure (Z. Song et al., 2000)